BGAM
ALXN

Boussard & Gavaudan Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boussard & Gavaudan Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,850
Closed -$278K – 133
2014
Q1 		$278K Buy
+1,850
New +$294K 0.17% 18

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Boussard & Gavaudan Asset Management's ALXN Position: Q2 2014 in Review

Boussard & Gavaudan Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 1,850 shares — an estimated $278K sold.

Boussard & Gavaudan Asset Management first reported a position in ALXN in Q1 2014 and held it in 1 quarter. The position peaked at $278K in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Boussard & Gavaudan Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Boussard & Gavaudan Asset Management sold 1,850 Alexion Pharmaceuticals shares in Q2 2014, an estimated $278K.
  • Boussard & Gavaudan Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Boussard & Gavaudan Asset Management's Alexion Pharmaceuticals position peaked at $278K in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Boussard & Gavaudan Asset Management's 13F filing for Q2 2014, filed 1 Aug 2014.